Denali Therapeutics Inc.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151…
Biotechnology
US, South San Francisco [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Denali Therapeutics Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2018 | -5.8900 | -1.337 | 0 | 30 | -88 | -183 | -90 | -20 | -90 | -20 | 15 | 28 |
| 2019 | -0.3900 | -2.081 | 129 | 31 | -36 | -186 | -46 | -178 | -46 | -200 | 32 | 29 |
| 2020 | -2.0700 | -1.539 | 26 | 92 | -197 | 41,419 | -213 | -61 | -406 | -63 | 46 | 85 |
| 2021 | 0.6500 | -2.265 | 335 | 75 | 71 | -178 | 62 | -173 | -149 | -181 | 60 | 48 |
| 2022 | -2.3900 | -2.621 | 48 | 109 | -290 | -242 | -295 | -233 | -301 | -248 | 79 | 74 |
| 2023 | -2.6000 | -0.995 | 108 | 337 | -325 | -419 | -330 | -256 | -347 | -273 | 90 | 81 |
| 2024 | -1.0600 | -2.532 | 330 | 21 | -145 | -347 | -179 | -14 | -196 | -14 | 86 | 19 |
| 2025 | - | -2.558 | - | 70 | - | -368 | - | -47 | - | -48 | - | 65 |
| 2026 | - | 2.F8X/td> | - | 2.F8X/td> | - | 2.F8X/td> | - | 2.F81/td> | - | 2.F81 | - | 2.F81 |
| 2027 | - | 1.F9X/td> | - | 1.F9X/td> | - | 1.F9X/td> | - | 1.F91/td> | - | 1.F91 | - | 1.F91 |
| 2028 | - | 0.F10X/td> | - | 0.F10X/td> | - | 0.F10X/td> | - | 0.F101/td> | - | 0.F101 | - | 0.F101 |